Literature DB >> 22451424

Distinct mutations in STXBP2 are associated with variable clinical presentations in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL5).

Julia Pagel1, Karin Beutel, Kai Lehmberg, Florian Koch, Andrea Maul-Pavicic, Anna-Katharina Rohlfs, Abdullah Al-Jefri, Rita Beier, Lilian Bomme Ousager, Karoline Ehlert, Ute Gross-Wieltsch, Norbert Jorch, Bernhard Kremens, Arnulf Pekrun, Monika Sparber-Sauer, Ester Mejstrikova, Angela Wawer, Stephan Ehl, Udo zur Stadt, Gritta Janka.   

Abstract

Familial hemophagocytic lymphohistiocytosis (FHL) is a genetically determined hyperinflammatory syndrome caused by uncontrolled immune response mediated by T-lymphocytes, natural killer (NK) cells, and macrophages. STXBP2 mutations have recently been associated with FHL5. To better characterize the genetic and clinical spectrum of FHL5, we analyzed a cohort of 185 patients with suspected FHL for mutations in STXBP2. We detected biallelic mutations in 37 patients from 28 families of various ethnic origins. Missense mutations and mutations affecting 1 of the exon 15 splice sites were the predominant changes detectable in this cohort. Patients with exon 15 splice-site mutations (n = 13) developed clinical manifestations significantly later than patients with other mutations (median age, 4.1 year vs 2 months) and showed less severe impairment of degranulation and cytotoxic function of NK cells and CTLs. Patients with FHL5 showed several atypical features, including sensorineural hearing deficit, abnormal bleeding, and, most frequently, severe diarrhea that was only present in early-onset disease. In conclusion, we report the largest cohort of patients with FHL5 so far, describe an extended disease spectrum, and demonstrate for the first time a clear genotype-phenotype correlation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22451424     DOI: 10.1182/blood-2011-12-398958

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies.

Authors:  Kai Lehmberg; Kim E Nichols; Jan-Inge Henter; Michael Girschikofsky; Tatiana Greenwood; Michael Jordan; Ashish Kumar; Milen Minkov; Paul La Rosée; Sheila Weitzman
Journal:  Haematologica       Date:  2015-08       Impact factor: 9.941

Review 2.  Perforin and granzymes: function, dysfunction and human pathology.

Authors:  Ilia Voskoboinik; James C Whisstock; Joseph A Trapani
Journal:  Nat Rev Immunol       Date:  2015-06       Impact factor: 53.106

3.  Hemophagocytic lymphohistiocytosis caused by dominant-negative mutations in STXBP2 that inhibit SNARE-mediated membrane fusion.

Authors:  Waldo A Spessott; Maria L Sanmillan; Margaret E McCormick; Nishant Patel; Joyce Villanueva; Kejian Zhang; Kim E Nichols; Claudio G Giraudo
Journal:  Blood       Date:  2015-01-06       Impact factor: 22.113

Review 4.  The biogenesis of lysosomes and lysosome-related organelles.

Authors:  J Paul Luzio; Yvonne Hackmann; Nele M G Dieckmann; Gillian M Griffiths
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-09-02       Impact factor: 10.005

5.  Weathering the storm: Improving therapeutic interventions for cytokine storm syndromes by targeting disease pathogenesis.

Authors:  Lehn K Weaver; Edward M Behrens
Journal:  Curr Treatm Opt Rheumatol       Date:  2017-02-07

6.  Late-onset severe chronic active EBV in a patient for five years with mutations in STXBP2 (MUNC18-2) and PRF1 (perforin 1).

Authors:  Jeffrey I Cohen; Julie E Niemela; Jennifer L Stoddard; Stefania Pittaluga; Helen Heslop; Elaine S Jaffe; Kennichi Dowdell
Journal:  J Clin Immunol       Date:  2015-05-07       Impact factor: 8.317

7.  Disrupted apical exocytosis of cargo vesicles causes enteropathy in FHL5 patients with Munc18-2 mutations.

Authors:  Georg F Vogel; Jorik M van Rijn; Iris M Krainer; Andreas R Janecke; Carsten Posovszky; Marta Cohen; Claire Searle; Prevost Jantchou; Johanna C Escher; Natalie Patey; Ernest Cutz; Thomas Müller; Sabine Middendorp; Michael W Hess; Lukas A Huber
Journal:  JCI Insight       Date:  2017-07-20

8.  Novel Patient with Late-Onset Familial Hemophagocytic Lymphohistiocytosis with STXBP2 Mutations Presenting with Autoimmune Hepatitis, Neurological Manifestations and Infections Associated with Hypogammaglobulinemia.

Authors:  Hossein Esmaeilzadeh; Mohammad Hasan Bemanian; Mohammad Nabavi; Saba Arshi; Morteza Fallahpour; Ilka Fuchs; Udo zur Stadt; Klaus Warnatz; Sandra Ammann; Stephan Ehl; Kai Lehmberg; Nima Rezaei
Journal:  J Clin Immunol       Date:  2014-12-10       Impact factor: 8.317

Review 9.  Genetic defects in cytolysis in macrophage activation syndrome.

Authors:  Mingce Zhang; Edward M Behrens; T Prescott Atkinson; Bita Shakoory; Alexei A Grom; Randy Q Cron
Journal:  Curr Rheumatol Rep       Date:  2014       Impact factor: 4.592

10.  The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis.

Authors:  Bernd Hartz; Rebecca Marsh; Kanchan Rao; Jan-Inge Henter; Michael Jordan; Lisa Filipovich; Peter Bader; Rita Beier; Birgit Burkhardt; Roland Meisel; Ansgar Schulz; Beate Winkler; Michael H Albert; Johann Greil; Gülsün Karasu; Wilhelm Woessmann; Selim Corbacioglu; Bernd Gruhn; Wolfgang Holter; Jörn-Sven Kühl; Peter Lang; Markus G Seidel; Paul Veys; Alexandra Löfstedt; Sandra Ammann; Stephan Ehl; Gritta Janka; Ingo Müller; Kai Lehmberg
Journal:  Blood       Date:  2016-04-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.